20 episodes

Engaging conversations with authors of articles from the Journal of Cutaneous Medicine and Surgery. JCMS is the peer-reviewed journal of the Canadian Dermatology Association.

JCMS: Author Interviews (Listen and earn CME credit) Canadian Dermatology Association

    • Business News

Engaging conversations with authors of articles from the Journal of Cutaneous Medicine and Surgery. JCMS is the peer-reviewed journal of the Canadian Dermatology Association.

    Implementing a "Skin Patient Charter of Rights” with Dr Harvey Lui

    Implementing a "Skin Patient Charter of Rights” with Dr Harvey Lui

    "They want to live without the fear of discrimination due to the appearance of their skin. In the context of June 2020 and Black Lives Matter and racism, this seems to be a very timely thing the patients have brought up."
    Dr Harvey Lui is JCMS Editor-in-Chief Dr Kirk Barber's guest on this edition of JCMS Author Interviews. They discuss Dr Lui's article, "Developing a Patient Charter for People Living With Conditions, Diseases, or Traumas Involving the Skin" in the March/April edition of the Journal of Cutaneous Medicine and Surgery. At the center of the discussion are the 8 principles for providing and receiving professional services for the skin in the healthcare setting as laid out in the Patient Charter, and why it's important that the Canadian Skin Patient Alliance Board was the driving force behind the charter.
    The JCMS article was co-authored with Arunima Sivanand, Kathryn Andrews-Clay.

    Dr Harvey Lui is Professor of Dermatology and Skin Science at the University of British Columbia. His special clinical and research interests are in phototherapy, lasers, and medical education. He's been past President of the CDA and the International League of Dermatological Societies.
    Music is by Lee Rosevere.
    JCMS Author Interviews is produced for the Canadian Dermatology Association by David McGuffin of Explore Podcast Productions in Ottawa. davidrcmcguffin@gmail.com

    • 29 min
    Why Empathy Helps Improve Patient Medication Adherence with Dr Steven Feldman

    Why Empathy Helps Improve Patient Medication Adherence with Dr Steven Feldman

    Dr Steven Feldman is JCMS Editor-in-Chief Dr Kirk Barber's guest on this latest edition of JCMS Author Interviews. The two have an in-depth conversation about the importance of empathy, or the appearance of empathy by doctors, as a means of getting patients to do a better job of treating themselves or their families.
    This conversation is based on the Article “Assessing the Effect of Clinical Trial Evidence and Anecdote on Caregivers’ Willingness to use Corticosteroids: A Randomized Controlled trial“ which appeared in the “January\February 2020 ” issue of the Journal of Cutaneous Medicine and Surgery.
    Dr. Feldman is a Professor of Dermatology, Pathology and Public Health Sciences at the Wake Forest University School of Medicine and a dermatologist and skin pathologist at Wake Forest Baptist Health in Winston-Salem, North Carolina.
    Music is by Lee Rosevere.
    JCMS Author Interviews is produced for the Canadian Dermatology Association by David McGuffin of Explore Podcast Productions in Ottawa.
    davidrcmcguffin@gmail.com

    • 26 min
    Canadian Burden of Skin Disease From 1990 to 2017: Results From the Global Burden of Disease 2017 Study

    Canadian Burden of Skin Disease From 1990 to 2017: Results From the Global Burden of Disease 2017 Study

    Dr. Kirk Barber interviews Dr. Aaron Drucker, one of the authors of "Canadian burden of skin disease from 1990 to 2017: Results from the Global Burden of Disease 2017 study," in the March-April edition of the Journal of Cutaneous Medicine and Surgery. Kirk and Aaron discuss some of the most important discoveries in the data found in the study and why it is a treasure trove for research and for putting together grant proposals.
    Accurate and up-to-date data on disease burden at the population level are crucial for understanding the important causes of death and disability. While mortality from skin disease is rare, many skin diseases are chronic and associated with substantial morbidity. There are estimates of incidence and prevalence of specific diseases such as psoriasis, atopic dermatitis, and melanoma, but there has been no comprehensive study of the burden of skin diseases and their associated disability in Canada, until now.
    The Global Burden of Disease (GBD) study aims to provide estimates of the fatal and nonfatal burden of disease. Metrics such as disability-adjusted life years (DALYs) can capture this burden, improving our understanding of skin disease and informing future research efforts and public policy. Skin disease was the 18th leading cause of global disease burden according to GBD 2015. The 2017 iteration of the GBD study measures health loss from death or disability resulting from 359 diseases and injuries in 195 countries and more than doubles the number of data sources compared with GBD 2010. GBD data provides a unique opportunity to understand the burden of skin disease in Canada. Herein, we present GBD 2017 results on morbidity, mortality, incidence, and prevalence for 18 skin and subcutaneous diseases, including skin cancers, in Canada from 1990 to 2017.
    Dr. Drucker is a Dermatologist at Women's College Hospital and the University of Toronto, focusing on eczema (atopic dermatitis) epidemiology.
    Music is by Lee Rosevere.
    JCMS Author Interviews is Produced by David McGuffin of Explore Podcast Productions in Ottawa.
    davidrcmcguffin@gmail.com
     
     
     

    • 24 min
    Canadian Dermatology Association

    Canadian Dermatology Association

    Dr. Catherine Besner-Morin talks with JCMS editor-in-chief Dr. Kirk Barber about the article on treating itch that she co-authored in the September-October 2019 issue of the Journal of Cutaneous Medicine and Surgery. Itch treatment is a major challenge in the dermatologist’s practice. We encounter patients suffering from pruritus on a regular basis, and often lack diverse treatment options to adequately respond to the patients’ needs. Dr. Besner-Morin discusses the novel pathways have been investigated in the last twenty years that are beyond the scope of histamine. Although most did not result in a molecule available on the Canadian market, it is interesting and important as health care providers to stay up to date with new neuronal pathways involved in itch transmission and potential new therapeutic options. In this interview Barber and Besner-Morin discuss pathways targeted in new topical treatments such as antagonist of proteinase-activated receptor-2, the endocannabinoid system, neurotrophins and tropomyosin-related kinase A receptor, the transient receptor potential-vanilloid or transient receptor potential-melastatine ion channels. New systemic therapies are now focusing on antagonizing the neurokinin receptor, modulating the opioidergic system, or targeting itch cytokines such as interleukin-31.
    Dr. Besner-Morin is a fellow of contact dermatitis at McGill University in Montreal and a Dermatologist at the University of Montreal.
    Music is by Lee Rosevere.
    JCMS Author Interviews is Produced by David McGuffin of Explore Podcast Productions in Ottawa.
    davidrcmcguffin@gmail.com
     

    • 32 min
    Treatment of Mycoplasma pneumoniae-Induced Rash and Mucositis With Cyclosporine

    Treatment of Mycoplasma pneumoniae-Induced Rash and Mucositis With Cyclosporine

    Dr. Michele Ramien talks with JCMS editor-in-chief Dr. Kirk Barber about the article she co-authored in the Nov-Dec 2019 issue of the Journal of Cutaneous Medicine and Surgery. In their conversation, Michele describes to Kirk the potential efficacy of cyclosporine A in the treatment of Mycoplasma pneumoniae-induced rash and mucositis, also known as MIRM. MIRM is a relatively newly recognized clinical entity that typically presents with predominant mucositis accompanied by variable cutaneous involvement 7-9 days after the onset of prodromal symptoms. There are no evidence-based guidelines for treatment, and current standards of care may include supportive therapy, antibiotics, corticosteroids, and intravenous immunoglobulin.
    Dr Ramien is a clinical associate professor of dermatology and community pediatrics at the University of Calgary. She is also vice chair of the Camp Liberté Society, a camp for children with skin disorders.
    Music is by Lee Rosevere.
    JCMS Author Interviews is Produced by David McGuffin of Explore Podcast Productions in Ottawa.
    davidrcmcguffin@gmail.com
     
     

    • 24 min
    Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments

    Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments

    Dr. Robert Gniadecki speaks with JCMS Editor-in-chief, Dr. Kirk Barber, about the article Gniadecki co-authored in the Sept/Oct 2019 edition of the Journal of Cutaneous Medicine and Surgery. They discuss two progressive primary cutaneous T-cell lymphomas for which there are no curative treatments, Mycosis fungoides and Sézary syndrome. Dr Gniadecki explains why Immunotherapy seems to be a promising avenue to achieve long-term disease control in CTCL, with compelling evidence indicating that Mycosis fungoides and Sézary syndrome are immunogenic lymphomas, which can be recognized by the patient’s immune system. They also discuss how current genomic techniques, such as estimating the mutational load by whole genome sequencing and neoantigen calling, are likely to provide clinically useful information facilitating personalized immunotherapy of CTCL.
    Dr. Robert Gniadecki is a professor of dermatology at the University of Alberta in Edmonton, where he is the director of the division of Dermatology and leads the Multidisciplinary Cutaneous Lymphoma Clinic.
    Theme music by Lee Rosevere
    Produced by David McGuffin, Explore Podcast Productions, Ottawa

    • 20 min

Top Podcasts In Business News

Listeners Also Subscribed To